Nuwellis (NUWE) — Supplier and Service Map for Investors

Nuwellis is a small-cap medical device company that develops and sells ultrafiltration systems (Aquadex) for fluid-overload therapy and monetizes through device sales, consumables and periodic capital raises. The company runs a lean operational model: it outsources manufacturing and leans on third‑party capital markets and proxy solicitation services to manage financing and governance. Investors should evaluate the supplier relationships below for operational continuity and the service partners for financing and governance risk. Learn more about vendor relationships and counterparty risk at https://nullexposure.com/.

Key investment takeaways up front

Manufacturing is outsourced and in transition. Nuwellis is moving assembly to a third-party manufacturer to cut costs and improve efficiencies.
Capital markets relationships are material to funding. Nuwellis relies on placement agents and underwriters to execute private placements and warrant financings.
Corporate services are standard for a Nasdaq-listed small cap. Transfer agent and proxy solicitation arrangements reflect typical public-company needs but also signal limited in‑house scale.

Bold claims above are supported by company disclosures and press reports; full relationship summaries follow.

Supplier and service relationships: what the record shows

KDI Precision Manufacturing

Nuwellis is transitioning manufacturing and assembly of the Aquadex SmartFlow console to KDI Precision Manufacturing with a go‑live planned for October, a move the company says will generate meaningful operational efficiencies and cost savings over the following 12 months. This shift was discussed on the 2025 Q2 earnings call and reported in FY2025 press coverage. (Earnings call transcript, 2025 Q2; press coverage FY2025.)

The Nasdaq Stock Market (Nasdaq)

Nuwellis’s common stock trades on the Nasdaq Capital Market under ticker NUWE; this listing frames the company’s disclosure and governance obligations and is referenced in the FY2026 preliminary proxy filing. (Preliminary proxy statement / Form PRE‑14A, FY2026.)

Alliance Advisors, LLC

Nuwellis engaged Alliance Advisors to assist in proxy solicitation and related advice for a services fee not to exceed $35,000, indicating the company uses boutique proxy advisors for shareholder engagement ahead of corporate votes. (Preliminary proxy statement, FY2026.)

Equiniti Trust Company, LLC

Equiniti Trust Company serves as Nuwellis’s transfer agent, providing shareholder recordkeeping and transfer services—an operational necessity for public companies. (Preliminary proxy statement, FY2026.)

Ladenburg Thalmann & Co., Inc.

Ladenburg acted as the underwriter and sole placement agent in multiple financing transactions: a June 9, 2025 Underwriting Agreement that placed common shares and various classes of warrants, and a January 2026 private placement and warrant inducement transaction priced at the market. Ladenburg’s repeated role underscores the company’s reliance on boutique investment banks for capital raises. (Underwriting Agreement disclosure, June 2025; GlobeNewswire release and QuiverQuant coverage, FY2026.)

E.F. Hutton & Co.

E.F. Hutton filed a complaint against Nuwellis in New York state court on February 11, 2026, alleging breach of an engagement letter for exclusive placement agent services and seeking monetary damages—an active legal dispute with potential financing implications. (Press coverage, The Globe and Mail, Feb 2026.)

What these relationships imply about Nuwellis’s operating model

The disclosed supplier and service relationships paint a consistent picture:

Contracting posture: outsourced and transactional. Nuwellis contracts out core operational functions—manufacturing assembly and capital-raising execution—rather than maintaining in‑house scale. The move to KDI and use of placement agents reflect a deliberate externalization of manufacturing and financing functions.
Concentration risk exists in execution. A manufacturing transition to a single contract manufacturer creates operational concentration during the go‑live and stabilization window; a failure to execute could disrupt production and margin improvement plans.
Criticality of service providers is high for near-term funding and governance. Placement agents, underwriters and proxy solicitors are not ancillary; they are critical to Nuwellis’s ability to execute financings that underpin liquidity and runway.
Maturity profile: small, capital-dependent, and actively refinancing. Financials show modest revenue (Revenue TTM ~$8.17M) and negative operating performance; the firm has relied on frequent financings, warrant instruments and boutique underwriters—characteristics of an early-stage, capital-dependent device company.

These operating-model signals are company-level observations: constraint analysis flags a manufacturer relationship with confidence and multiple service_provider signals tied to IT/cybersecurity and placement agency activity. Specifically, company disclosures reference third‑party manufacturers and the engagement of placement agents such as Roth Capital and Ladenburg in prior financings, and the use of third‑party IT/cybersecurity expertise in operational tooling.

For a deeper counterparty map and to monitor changes in supplier concentration or new financing partners, visit https://nullexposure.com/.

How investors should prioritize monitoring and risk mitigation

Track the KDI go‑live and early production metrics. Operational efficiency gains are the investment case driver; missed timelines or quality issues would increase cash burn and capex needs.
Monitor legal and financing headlines tied to placement agents. The E.F. Hutton suit and repeated placement activity with Ladenburg are governance and execution signals—legal friction or loss of placement partners would elevate funding risk.
Watch cash runway and financing terms. Given negative operating cash flow and small market capitalization, availability and price of capital will determine upside or dilution risk.
Confirm continuity of corporate services (transfer agent, proxy solicitor). These partners are inexpensive but operationally necessary; abrupt changes can complicate shareholder communications and proxy processes.

Actionable checklist for operators and investors

Verify manufacturing KPIs and initial yield after KDI go‑live; request completion dates and defect metrics.
Review recent financing agreements, underwriter commitments and outstanding warrant economics to model dilution scenarios.
Monitor the E.F. Hutton case docket for potential financial exposure and precedent on placement agent disputes.

For an uninterrupted view of counterparties and to build a tailored monitoring dashboard, explore vendor mapping tools at https://nullexposure.com/.

Final read: what matters most now

Nuwellis is executing a pragmatic pivot: outsourcing manufacturing to reduce cost and relying on boutique capital markets partners to supply liquidity. The primary risks are execution of the manufacturing transition and the company’s near‑term ability to access capital on acceptable terms. Investors should treat supplier continuity and placement‑agent relationships as central to the equity thesis rather than peripheral details.

If you manage capital or operate supplier governance, use the contact and contract signals in this piece as the starting point for vendor diligence and monitoring: https://nullexposure.com/.

NUWE supplier relationships